Patent Assignment
Reel/Frame 042377/0696
Assignment of Assignor's Interest
Recorded: 2017-05-01
Pages: 19
Assignor
MERRIMACK PHARMACEUTICALS, INC.
Executed: 2017-04-03
Assignee
IPSEN BIOPHARM LTD.
190 BATH ROAD, SOUGH BERKSHIRE, SL1 3XE, UNITED KINGDOM
Covered Properties
(76)
Liposomes useful for drug delivery
Application:
60/567,921 →
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Application:
61/659,211 →
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Application:
61/784,382 →
Treatment of Breast Cancer with Liposomal Irinotecan
Application:
62/089,685 →
Methods for Improving the Pharmacokinetics and Therapeutic Index of Sustained Release Drug Therapies
Application:
62/147,389 →
Combination Therapy for Cancer Treatment
Application:
62/207,709 →
Combination Therapy for Cancer Treatment
Application:
62/207,760 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/208,209 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/216,736 →
Liposomes with Improved Stability
Application:
62/242,835 →
Liposomes with Improved Stability
Application:
62/242,873 →
Irinotecan liposomes with improved stability
Application:
62/244,061 →
Liposomes with Improved Stability
Application:
62/244,082 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And
Application:
62/265,409 →
Combination Therapy for Cancer Treatment
Application:
62/269,511 →
Combination Therapy for Cancer Treatment
Application:
62/269,756 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/273,244 →
Treatment of Pancreatic Cancer with Liposomal Irinotecan
Application:
62/278,751 →
Treatment of Pancreatic Cancer with Liposomal Irinotecan
Application:
62/281,458 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/281,473 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/302,341 →
PARP Inhibitor and Irinotecan Liposome Combination Therapy for Cancer Treatment
Application:
62/308,924 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/323,245 →
Combination Therapy for Cancer Treatment
Application:
62/323,422 →
Treatment of Pancreatic Cancer with Liposomal Irinotecan
Application:
62/328,830 →
Mechanism Based Population Pharmacokinetics of Liposomal Irinotecan
Application:
62/338,324 →
Treatment of Pancreatic Cancer with Liposomal Irinotecan
Application:
62/341,223 →
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
62/343,313 →
Treatment of Triple Negative Breast Cancer with Liposomal Irinotecan
Application:
62/351,193 →
Treatment of Pancreatic Cancer with Liposomal Irinotecan
Application:
62/355,640 →
Treatment of Breast Cancer with Liposomal Irinotecan
Application:
62/430,470 →
Population Pharmacokinetics of Liposomal Irinotecan
Application:
62/433,687 →
Liposomes Useful for Drug Delivery to the Brain
Application:
14/151,632 →
Publication:
US 2014/0127136
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Application:
14/879,358 →
Publication:
US 2016/0030342
Liposomes Useful for Drug Delivery
Application:
14/964,239 →
Publication:
US 2016/0081928
Treatment of Breast Cancer with Liposomal Irinotecan
Application:
14/964,571 →
Publication:
US 2016/0346272
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Application:
14/979,666 →
Publication:
US 2016/0106672
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Application:
15/059,640 →
Publication:
US 2016/0228428
Liposomes Useful for Drug Delivery
Application:
15/227,561 →
Publication:
US 2016/0339014
Liposomes Useful for Drug Delivery
Application:
15/227,631 →
Publication:
US 2016/0338956
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Application:
15/241,106 →
Publication:
US 2017/0049775
Methods for Treating Pancreatic Cancer Using Combination Therapies
Liposomes Useful for Drug Delivery to the Brain
Liposomal Irinotecan Preparations
Application:
15/331,318 →
Liposomal Irinotecan Compositions
Application:
15/331,393 →
Liposomal Irinotecan Preparations
Application:
15/331,648 →
Combination Therapy for Cancer Treatment
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Application:
15/341,377 →
Publication:
US 2017/0065578
Methods for Treating Pancreatic Cancer Using Combination Therapies
Application:
15/341,619 →
Publication:
US 2017/0049768
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Application:
15/363,923 →
Publication:
US 2017/0079912
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Application:
15/364,021 →
Publication:
US 2017/0079914
Treatment of Breast Cancer with Liposomal Irinotecan
Application:
15/375,039 →
Publication:
US 2017/0151226
Treatment of Pancreatic Cancer with Liposomal Irinotecan
Application:
15/403,441 →
Publication:
US 2017/0202840
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery to the Brain
Liposomes Useful for Drug Delivery
Liposomes Useful for Drug Delivery
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Liposomes Useful for Drug Delivery
PCT:
PCT/US2005/015349 ↗
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
PCT:
PCT/US2013/045495 ↗
Treatment of Breast Cancer with Liposomal Irinotecan
PCT:
PCT/US2015/064491 ↗
Methods for Improving the Pharmacokinetics and Therapeutic Index of Suctained Release Drug Therapies
PCT:
PCT/US2016/027515 ↗
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
PCT:
PCT/US2016/047727 ↗
Combination Therapy for Cancer Treatment
PCT:
PCT/US2016/047814 ↗
Combination Theraby for Cancer Treament
PCT:
PCT/US2016/047827 ↗
Stabilized Camptothecin Compound Compositions
PCT:
PCT/US2016/057247 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 28, 2004
From: HONG, KEELUNG; DRUMMOND, DARYL C.; KIRPOTIN, DMITRI B.
To: HERMES BIOSCIENCES, INC.
Reel/Frame 014801/0451 →
Assignment of Assignor's Interest
Jul 19, 2012
From: BAYAVER, ELIEL; DHINDSA, NAVREET; FITZGERALD, JONATHAN BASIL; LAIVINS, PETER
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 028590/0635 →
Assignment of Assignor's Interest
Mar 29, 2013
From: BAYEVER, ELIEL; DHINDSA, NAVREET; FITZGERALD, JONATHAN BASIL; LAIVINS, PETER
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 030114/0175 →
Assignment of Assignor's Interest
May 15, 2013
From: BAYEVER, ELIEL
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 030418/0066 →
Merger
Aug 27, 2014
From: HERMES BIOSCIENCES, INC.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033623/0992 →
Assignment of Assignor's Interest
Aug 27, 2014
From: HONG, KEELUNG; DRUMMOND, DARYL C.; KIRPOTIN, DMITRI
To: HERMES BIOSCIENCES, INC.
Reel/Frame 033623/0874 →
Assignment of Assignor's Interest
Jun 3, 2015
From: BAYEVER, ELIEL; FITZGERALD, JONATHAN BASIL; KIM, JAEYEON; KLINZ, STEPHAN
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 035777/0948 →
Merger
Jun 29, 2015
From: HERMES BIOSCIENCES, INC.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 035926/0526 →
Security Interest
Dec 28, 2015
From: MERRIMACK PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 037394/0285 →
Assignment of Assignor's Interest
Jan 4, 2016
From: HONG, KEELUNG; DRUMMOND, DARYL C.; KIRPOTIN, DMITRI
To: HERMES BIOSCIENCES, INC.
Reel/Frame 037400/0786 →
Merger
Jan 4, 2016
From: HERMES BIOSCIENCES, INC.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 037400/0836 →
Assignment of Assignor's Interest
Apr 13, 2016
From: YEH, CHANG-JING GRACE
To: PHARMAENGINE, INC.
Reel/Frame 038270/0495 →
Assignment of Assignor's Interest
Apr 13, 2016
From: DE GRAMONT, AIMERY
To: GROUPE COOPÉRATEUR MULTIDISCIPLINAIRE EN ONCOLOGIE
Reel/Frame 038271/0320 →
Assignment of Assignor's Interest
Apr 13, 2016
From: KIM, JAEYEON; KLINZ, STEPHAN G.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038270/0340 →
Assignment of Assignor's Interest
Apr 27, 2016
From: BAYEVER, ELIEL; FITZGERALD, JONATHAN BASIL; KIM, JAEYEON; KLINZ, STEPHAN G.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038395/0711 →
Assignment of Assignor's Interest
Apr 27, 2016
From: DRUMMOND, DARYL C.; KIRPOTIN, DMITRI B.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038397/0298 →
Assignment of Assignor's Interest
Apr 27, 2016
From: BAYEVER, ELIEL; DHINDSA, NAVREET; FITZGERALD, JONATHAN BASIL
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038396/0850 →
Assignment of Assignor's Interest
Apr 27, 2016
From: BAYEVER, ELIEL; FITZGERALD, JONATHAN BASIL; KIM, JAEYEON; KLINZ, STEPHAN G.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038395/0807 →
Assignment of Assignor's Interest
Apr 27, 2016
From: BAYEVER, ELIEL; DHINDSA, NAVREET; FITZGERALD, JONATHAN BASIL; LAIVINS, PETER N.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038397/0037 →
Assignment of Assignor's Interest
Apr 27, 2016
From: DRUMMOND, DARYL C.; FITZGERALD, JONATHAN BASIL
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038397/0377 →
Assignment of Assignor's Interest
Aug 29, 2016
From: BLANCHETTE, SARAH F.; DRUMMOND, DARYL C.; FITZGERALD, JONATHAN BASIL; MOYO, VICTOR
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 039566/0398 →
Assignment of Assignor's Interest
Aug 29, 2016
From: BAYEVER, ELIEL; BLANCHETTE, SARAH F.; FITZGERALD, JONATHAN BASIL; GADDY, DANIEL F.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 039566/0620 →
Assignment of Assignor's Interest
Aug 29, 2016
From: BAYEVER, ELIEL; DHINDSA, NAVREET; FITZGERALD, JONATHAN BASIL; LAIVINS, PETER
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 039861/0428 →
Assignment of Assignor's Interest
Aug 29, 2016
From: MOYO, VICTOR
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 039861/0506 →
Assignment of Assignor's Interest
Oct 13, 2016
From: HAYES, MARK EAMON; NOBLE, CHARLES; KESPER, KEVIN; AWAD, ANTOINE M.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 040007/0688 →